论文部分内容阅读
目的比较辛伐他汀联合阿司匹林与单用阿司匹林预防缺血性脑血管病复发的疗效。方法 140例缺血性脑卒中和短暂性脑缺血发作(TIA)患者随机分入治疗组70例(辛伐他汀40 mg,每日1次,联合肠溶阿司匹林100 mg,每日1次)和对照组70例(肠溶阿司匹林100 mg,每日1次)。观察两组脑缺血事件发生率。结果治疗组脑梗死患者的1年复发率显著低于对照组(7.5%比22.5%,P<0.05),TIA 患者1年内反复发作2次的比例显著低于对照组(6.7%比30%,P<0.05);TIA 发展为脑梗死的患者比例有减少(6.7%比20%,P<0.05)。结论辛伐他汀联合阿司匹林预防缺血性脑血管病复发的效果明显优于单独阿司匹林,他汀类药物对缺血性脑血管病二级预防值得临床推广。
Objective To compare the efficacy of simvastatin with aspirin and aspirin alone in the prevention of recurrent ischemic cerebrovascular disease. Methods A total of 140 patients with ischemic stroke and transient ischemic attack (TIA) were randomly divided into treatment group (simvastatin 40 mg, once daily, combined with enteric-coated aspirin 100 mg once daily) And control group of 70 patients (enteric-coated aspirin 100 mg once daily). The incidence of cerebral ischemic events in both groups was observed. Results The 1-year recurrence rate of patients with cerebral infarction in the treatment group was significantly lower than that of the control group (7.5% vs 22.5%, P <0.05). The proportion of recurrent TIA patients in 2 years was significantly lower than that in the control group (6.7% vs 30% P <0.05). The proportion of TIA patients who developed cerebral infarction was decreased (6.7% vs. 20%, P <0.05). Conclusion Simvastatin combined with aspirin in the prevention of recurrent ischemic cerebrovascular disease was significantly better than aspirin alone, and statins for secondary prevention of ischemic cerebrovascular disease worthy of clinical promotion.